 In a context of changing regulations, the rise of auto medication and the generalization of generics drugs, pharmaceuticals are required to better allocate resources and build performance models.
Soft Computing helps pharmaceuticals to better identify and quantify the effects of sales and marketing, operational business levers:
- Targeting (doctors and pharmacies),
- Strategic allocation of marketing resources,
- Design and implementation of relationship programs with suppliers,
- Identification of expectations: health professionals and patients; and determine progressive business levers,
- Optimization of sectoring, and performance efficiency of sales visits.
- Treatment satisfaction studies using advanced statistical analysis.
Elsewhere, Soft Computing has helped public healthcare providers for over ten years: evolutions in treatment quality while taking into account patient needs and satisfaction:
Selected Examples
- Alliance Santé: Designed and realized follow-up panels for several thousand pharmacies, measuring customer satisfaction and customer perception of competitors.
- Astra Zeneca: Optimized the marketing mix, through the identification of prescription levers and performance analysis.
- Bristol-Myers Squibb: Identified and profiled thousands of pharmacies distributing products to patients at a critical stage of cardio vascular disease treatment.
- CNAM / TS: Helped design and implement an improvement plan for service quality for health professionals.
- GlaxoSmithKline: Carried out data mining with the goal of increasing customer knowledge within the field of the central nervous system and antibiotic therapy.
- Ministry of Health and Anti Cancer League: The "Cancer Plan": audited pilot project and provided development consulting.
- Novartis: Designed and implemented system for measuring the sources of hospital treatment.
- “Generics” laboratory: Designed and implemented "pharmacy” data warehouse, as well as marketing and sales tools.
Main References
Alliance Santé, Astra Zeneca, Aventis, Biogaran, Bristol-Myers-Squibb, Fédération Nationale des Centres de Lutte Contre le Cancer, GlaxoSmithKline, Johnson & Johnson, Novartis, Orpea, Ratiopharm.
|
